The global bioresorbable polymers market is estimated to account for USD 1.7 billion in 2025. It is anticipated to grow at a CAGR of 10.9% during the assessment period and reach a value of USD 4.9 billion by 2035.
| Metrics | Values |
|---|---|
| Industry Size (2025E) | USD 1.7 billion |
| Industry Value (2035F) | USD 4.9 billion |
| Value-based CAGR (2025 to 2035) | 10.9% |
During 2024, the bioresorbable polymer experienced substantial advancements
Product Developments: Sophisticated products with enhanced mechanical properties and targeted degradation entered the industry from manufacturers, targeting sophisticated orthopedic and cardiovascular applications.
Regulatory Clearances: Various bioresorbable medical devices received regulatory clearances, making them available for commercialization and application in clinics.
Collaborations: Major industry players collaborated with research institutions to accelerate the development of new bioresorbable materials, with an eye to expanding their range of application.
Market Growth: Developing economies, particularly in Asia-Pacific, showed increasing utilization of bioresorbable polymers, driven by improved healthcare infrastructure and growing awareness among healthcare professionals.
Explore FMI!
Book a free demo
Technology Advances: Further research will more than likely create polymers with tailored degradation patterns, increasing their application in regenerative medicine and tissue engineering.
Regulatory Incentives: Efficient regulatory pathways are likely to accelerate approval for new bioresorbable materials, facilitating entry and innovation.
Market Penetration: Greater use of this products by various fields in medicine, including wound healing and drug delivery, is most likely to drive expansion.
Sustainability Emphasis: Sustainability emphasis on the environment in medical materials can also drive the adoption of bioresorbable polymers, supporting global sustainability objectives.
A recent survey by Future Market Insights captured information from influential stakeholders in the industry, such as medical device manufacturers, healthcare providers, and regulatory specialists. Results indicated an emerging consensus on the growing application of bioresorbable materials, particularly in orthopedic and cardiovascular applications.
Survey participants stressed that the principal driving forces behind the trend are lower demand for repeat surgeries, enhanced patient outcomes, and advancements in polymer technology for enhanced material strength and degradation control.
One more key finding of the survey was increasing need for custom bioresorbable polymer formulations for a particular medical purpose. Medical professionals emphasized the need for tightly controlled material degradation timetables to accommodate the body's healing mechanism.
Many producers are putting R&D money into creating next-generation polymers with increased biocompatibility and strength to open the doors to broad uses in tissue engineering and regenerative medicine.Since the business is rapidly changing, it is vital for firms in the industry to keep track of existing trends, new technologies, and regulatory updates.
Government regulations and mandatory certifications play a pivotal role in shaping the indsutry across various countries. Below is a table summarizing the impact of these policies and the required certifications by country:
| Countries/Region | Government Regulations and Mandatory Certifications |
|---|---|
| United States | The USA Department of Agriculture (USDA) oversees the BioPreferred® Program, established under Section 9002 of the Farm Security and Rural Investment Act. This program mandates federal agencies and contractors to prioritize biobased products, including bioresorbable polymers, in their procurement processes. Products must meet specific biobased content standards to qualify for mandatory federal purchasing. |
| European Union | The EU enforces stringent regulations on biodegradable plastics, which encompass bioresorbable polymers. Compliance with standards such as EN 13432 is mandatory, ensuring that products meet criteria for biodegradability, compostability, and eco-toxicity. Additionally, certifications like "OK Biodegradable Marine," based on ASTM D7081, require at least 90% biodegradation within six months, though this certification is considered premature by some stakeholders. |
| Germany | Germany adheres to EU regulations and has implemented additional national policies promoting the use of biobased and biodegradable plastics. The country supports certifications under the International Sustainability and Carbon Certification (ISCC) system, which evaluates ecological and social sustainability, compliance with laws, greenhouse gas emissions, and good management practices. |
| Netherlands | The Netherlands has explored implementing mandatory requirements for recycled or biobased plastic content in products. Studies have assessed the feasibility and environmental impacts of such mandates, focusing on increasing the percentage of recyclate or biobased materials in new products. |
| Global | International standards, such as ISO 14001, provide a framework for environmental management systems applicable to manufacturers of bioresorbable polymers. Certifications under this standard demonstrate a commitment to environmental sustainability and compliance with relevant regulations. |
These regulations and certifications ensure that product meet environmental and safety standards, facilitating their acceptance and use in various applications worldwide.
| 2020 to 2024 | 2025 to 2035 |
|---|---|
| Growing awareness of bioresorbable materials, improved patient outcomes, and advancements in polymer degradation technology boosted adoption. The COVID-19 pandemic initially slowed growth but later fueled innovation in biocompatible materials. | Innovations in nanotechnology and personalized medicine are expected to propel growth. The demand for sustainable, bio-based alternatives to synthetic polymers will also play a crucial role. |
| The period saw gradual regulatory acceptance, with approvals for bioresorbable stents and sutures increasing. However, complex approval processes slowed industry entry for new products. | Streamlined approval processes and clearer regulatory pathways are anticipated, encouraging innovation and reducing time-to-industry for new bioresorbable products. |
| Companies invested heavily in R&D, focusing on improving polymer properties and degradation rates. Strategic collaborations between industry players and research institutions increased. | Investments rise significantly, with advancements in 3D printing and smart biomaterials enhancing product capabilities. |
| Orthopedic fixation devices, sutures, and cardiovascular stents dominated the industry. Demand was primarily driven by North America and Europe. | Expansion into wound healing, regenerative medicine, and controlled drug delivery is expected. Emerging industry in Asia-Pacific and Latin America will witness higher adoption rates. |
| High production costs, limited product awareness in developing nations, and stringent regulatory requirements hindered industry growth. | While cost concerns will persist, economies of scale and material innovations will help reduce expenses. Companies that focus on sustainability and patient-specific solutions will gain a competitive edge. |
Based on product, it is divided into polysaccharides, proteins bioresorbable, polylactic acid, polyglycolic acid, polycaprolactone, and others. Polylactic acid (PLA) is the most common bioresorbable polymer because of its high biocompatibility, mechanical properties, and controlled rate of degradation. It is widely applied in medicine as sutures, orthopedic devices, and drug delivery systems.
PLA breaks down into lactic acid, a naturally occurring compound in the human body, and thus it is safe for biomedical applications. Relative to polysaccharides and proteins, PLA provides greater structural integrity, which is essential for load-bearing medical devices.
Polyglycolic acid (PGA) and polycaprolactone (PCL) are also widely used, frequently in blends with PLA, to modulate degradation rates and mechanical properties. Nevertheless, PLA is the most prevalent choice because of its established regulatory approval, cost-effectiveness, and applicability in both medical and biodegradable packaging applications.
Based on application, the industry is divided into drug delivery, orthopedics, and others. Bioresorbable polymers are employed to a larger extent in orthopedics than drug delivery because they play an important role as temporary implants, fixation devices, and bone scaffolds.
The polymers such as polylactic acid (PLA), polyglycolic acid (PGA), and polycaprolactone (PCL) exhibit good mechanical strength and sequentially degrade as bone repair occurs, which avoids surgical intervention for device removal. Their capacity to retain structural integrity for a specified duration makes them perfect for screws, plates, and pins in fracture fixation and reconstructive surgery.
Although they are increasingly being used in drug delivery, especially for controlled-release products, their application in orthopedics is still predominant because of the strong demand for bioabsorbable fixation devices and the growing incidence of orthopedic injuries and surgeries globally.
| Countries | CAGR (2025 to 2035) |
|---|---|
| USA | 10.5% |
| UK | 9.8% |
| France | 9.5% |
| Germany | 9.7% |
| Italy | 9.2% |
| South Korea | 10.0% |
| Japan | 9.6% |
| China | 11.0% |
The USA is likely to experience a CAGR of about 10.5% during the period of 2025 to 2035 in the industry. This is due to the advanced healthcare facilities in the country, rising usage of bioresorbable materials in the medical sector, and high research and development investments.
The USA dominates in the creation and commercialization of medical devices using bioresorbable polymers, especially in orthopedic and cardiovascular industries. The availability of key market players and supportive regulatory guidelines further enhance market growth. Moreover, increased awareness among patients and healthcare professionals regarding the advantages of bioresorbable implants also supports the positive growth of the industry.
The United Kingdom’s industry is expected to grow at a CAGR of approximately 9.8% for the forecast period. The UK's aggressive focus on healthcare innovation and rising use of sophisticated medical technologies make this growth possible.
Government support for biomedical research and development, as well as partnerships between academic institutions and industry leaders, strengthen the environment. The National Health Service's (NHS) commitment to enhancing patient outcomes through sophisticated medical solutions also fuels the need for product across different applications, such as drug delivery and orthopedic implants.
France is expected to have a CAGR of around 9.5% in the industry during 2025 to 2035. Its well-developed healthcare infrastructure and robust pharmaceutical sector are responsible for the uptake of bioresorbable materials. French research organizations and industries are also intensively involved in creating new bioresorbable polymer-based medical devices.
Support from the government for medical research and emphasis on minimally invasive procedures further support industry growth. The growing incidence of chronic diseases requiring surgical procedures also increases the demand for bioresorbable implants and devices.
The industry in Germany is anticipated to expand at a CAGR of approximately 9.7% over the forecast period. The strong medical device sector in the country and focus on healthcare technology advancements drive this growth. German firms are leaders in the development of high-quality bioresorbable polymer products, especially for orthopedic and cardiovascular applications.
The use of bioresorbable polymers in medical devices fits the focus of Germany on precision medicine and patient-individualized treatment solutions. Also, partnerships between industry and research centers allow ongoing innovation in this field.
Italy is expected to experience a CAGR of around 9.2% in the bioresorbable polymers during 2025 to 2035. The expanding healthcare industry and rising investments in medical research in the country drive growth. Italian firms are investigating the application of bioresorbable polymers in different medical applications, such as tissue engineering and regenerative medicine.
Advanced healthcare technologies are encouraged by government initiatives and partnerships with global research organizations, which drive the development and implementation of bioresorbable polymer-based solutions.
Bioresorbable polymers in South Korea is forecast to expand with a CAGR of approximately 10.0% over the forecast period. South Korea's highly developed technology infrastructure and substantial focus on biomedical research drive growth.
The active adoption of high-tech medical technology by the nation, coupled with government support through research and development incentives, propels innovation within bioresorbable polymers. South Korean firms actively work on the development of bioresorbable medical devices, especially orthopedic and drug delivery systems.
Japan will grow at a CAGR of around 9.6% in the industry for bioresorbable polymers between 2025 and 2035. Japan's high rate of chronic disease incidence and aging population propel the demand for innovative medical solutions, such as bioresorbable implants.
The robust pharmaceutical and medical device industries of Japan are placing investments in bioresorbable polymer technologies. Government policies to encourage healthcare innovation and the implementation of minimally invasive surgical techniques also contribute to the growth in the industry.
China's bioresorbable polymers is expected to expand at a strong CAGR of approximately 11.0% over the forecast period. The growth is fueled by the country's growing healthcare infrastructure and rising investments in medical R&D.
Chinese firms are quickly embracing bioresorbable polymers in different medical applications, aided by government support for cutting-edge healthcare technologies. The vast patient base and growing awareness of the advantages of bioresorbable medical devices also support industry growth.
In 2024, the bioresorbable polymers saw substantial advancements as top companies introduced strategic measures to improve their positions. Evonik Industries AG, a major player in the industry, increased the production capacity for polylactic acid (PLA) to address the increased demand for the material in medical applications. This increase was aimed at increasing the company's capability to deliver quality bioresorbable materials to be used in orthopedic implants and drug delivery systems.
Corbion NV emphasized innovation with the launch of a new family of polyglycolic acid (PGA) products specifically engineered for surgical sutures and tissue engineering. These products were conceived to provide better biocompatibility and controlled rate of degradation in response to needs in surgical use. The ability of the company to invest in research and development allowed it to respond to changing needs of the medical community.
Foster Corporation, which deals in biomedical polymers, introduced a line of proprietary polymer blends in 2024. The blends were designed to maximize mechanical properties and degradation profiles, which made them ideal for use in a range of medical applications, such as cardiovascular stents and wound healing devices. By working closely with medical device companies, Foster Corporation sought to provide materials that meet the industry's high standards.
Poly-Med Inc., which specializes in bioresorbable materials, partnered with a prominent medical devices company on a strategic collaboration to co-design next-generation bioresorbable vascular scaffolds. The alliance aimed at merging Poly-Med's material science expertise with the partner's clinical know-how to put novel solutions in the marketplace. The alliance highlighted the value of cross-industry collaboration in the development of medical technologies.
The bioresorbable polymers is a subset of the wider biomedical materials and advanced polymers category, which is a subset of the global healthcare and materials science sectors. The industry is subject to significant macroeconomic influences including healthcare expenditure, regulatory measures, technological innovation, and population trends.
At the macroeconomic level, the increasing global healthcare spending is a major growth driver. Governments and private healthcare systems are investing more in sophisticated medical technologies, such as bioresorbable materials, to enhance patient outcomes and lower long-term treatment costs. The trend toward minimally invasive procedures and biodegradable implants follows this pattern, as bioresorbable polymers obviate the need for follow-up procedures to remove implants.
Furthermore, the growing ageing population across the globe is generating chronic demand for orthopedic, cardiovascular, and drug delivery use cases, where bioresorbable materials are the key. Growth of Asia-Pacific and Latin America are experiencing increased rates of adoption with rising healthcare infrastructure and increasing disposable incomes.
But macroeconomic issues like inflation, supply chain disruptions, and regulatory complexity could affect industry growth. Raw material costs and compliance with rigorous FDA and EU regulations drive product pricing and industry entry strategies. Despite these, ongoing R&D spending and technological innovations will keep fueling this growth.
Expansion in Emerging Markets
Though North America and Europe lead the bioresorbable polymers today, Asia-Pacific and Latin America offer high-growth potential. China, India, and Brazil are making growing investments in healthcare infrastructure and biomedical research, making them key targets for expansion.
Strategic Recommendation: Local partnerships with hospitals and medical device manufacturers should be formed by stakeholders, taking advantage of government incentives for local production to decrease dependence on imports and regulatory hurdles.
Innovation in Products in Orthopedics and Cardiovascular Applications
The orthopedic and cardiovascular sectors represent the most significant application for bioresorbable polymers. With the increasing requirement for patient-tailored resorption rates matching the individual-specific healing schedules, a greater need arises for adaptive degradation rates for implants and scaffolds.
Strategic Suggestion: Business entities would benefit from marketing hybrid polymer mixes (such as PLA-PGA blends) which can provide tuneable mechanical performances and controlled levels of resorption for enhanced outcomes and fewer complications for patients.
Leveraging 3D Printing for Personalized Medical Devices
3D printing is transforming patient-specific implants and drug delivery devices. 3D-printable bioresorbable polymers offer tremendous benefits in precision medicine. Strategic Recommendation: Bio-printing partnerships with research centers should be invested in by stakeholders in order to create personalized scaffolds, stents, and tissue engineering products in a way that better matches the patient and heals faster.
Evonik Industries
Corbion NV
BASF SE
DSM Biomedical
Ashland Global Holdings
Poly-Med, Inc.
Foster Corporation
Durect Corporation (Lactel Absorbable Polymers)
Mitsubishi Chemical Corporation
Teijin Limited
Bioresorbable polymers have a broad range of applications in orthopedic implants, cardiovascular stents, drug delivery systems, wound healing devices, and tissue engineering. The materials progressively break down in the body, thus avoiding the need for surgical extraction and minimizing post-surgery complications.
Polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), and polydioxanone (PDO) are the most widely applied bioresorbable polymers. Their biocompatibility and controllable degradation rates make them suitable for biomedical applications.
The increasing demand for minimally invasive procedures, rising incidence of orthopedic and cardiovascular diseases, polymer technology advancements, and regulatory clearances for bioresorbable medical devices are key drivers of adoption.
Regulatory challenges, high cost of production, inconsistency in degradation rates, and low mechanical strength for load-bearing applications are some of the challenges. Firms are actively engaged in enhancing polymer formulations to overcome these challenges.
Because the polymers can naturally degrade within the body, they minimize medical waste as well as secondary surgeries. Also, most bioresorbable polymers are made from renewable resources, which makes them a more environmentally friendly choice over having a permanent implant.
With respect to product, the market is classified into polysaccharides, proteins bioresorbable, polylactic acid, polyglycolic acid, polycaprolactone, and others.
In terms of application, the market is divided into drug delivery, orthopedics, and others.
In terms of region, the market is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA.
Octyl Octanoate Market Growth - Trends & Forecast 2025 to 2035
Organo-Modified Bentonite Market Growth – Trends & Forecast 2025 to 2035
Petroleum Jelly Market Growth - Trends & Forecast 2025 to 2035
Magnesium Sulfate Market Growth - Trends & Forecast 2025 to 2035
N-Propyl Acetate Market Growth – Trends & Forecast 2025 to 2035
Lubricant Additives Market Growth – Trends & Forecast 2025 to 2035
Bioresorbable Polymers Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
